The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
Liraglutide is a glucagon-like peptide-1 (GLP-1) analog marketed for the treatment of type 2 diabetes. Besides lowering blood glucose, liraglutide also reduces body weight. It is not fully understood how liraglutide induces weight loss or to what degree liraglutide acts directly in the brain. Here, we determined that liraglutide does not activate GLP-1-producing neurons in the hindbrain, and liraglutide-dependent body weight reduction in rats was independent of GLP-1 receptors (GLP-1Rs) in the vagus nerve, area postrema, and paraventricular nucleus. Peripheral injection of fluorescently labeled liraglutide in mice revealed the presence of the drug in the circumventricular organs. Moreover, labeled liraglutide bound neurons within the arcuate nucleus (ARC) and other discrete sites in the hypothalamus. GLP-1R was necessary for liraglutide uptake in the brain, as liraglutide binding was not seen in Glp1r(-/-) mice. In the ARC, liraglutide was internalized in neurons expressing proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART). Electrophysiological measurements of murine brain slices revealed that GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling. Collectively, our findings indicate that the GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1R and GIP-R have been identified in brain regions involved in the regulation of appetite, satiety, food/energy intake and energy expenditure, which is consistent with the significant impact on body weight observed with incretin therapy.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These studies have demonstrated that the principal sites of action accessible to these drugs are GLP-1R neurons in circumventricular organs, particularly the AP and ME, and those in immediately adjacent regions—the NTS and arcuate nucleus of the hypothalamus (16, 51, 63‐66).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The individual necessity of distinct GLP-1R neuron populations for the anorectic and weight loss effects of GLP-1RAs has now been claimed by multiple studies using various loss-of-function approaches in rodents (47, 50‐54, 69).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical studies also indicate that tanycytes, specialized glial cells within the CNS, may facilitate the transportation of peripheral GLP-1RAs, such as semaglutide, into the CNS, bypassing the blood-brain barrier to access appetite-regulating hypothalamic regions such as the arcuate nucleus (60, 61).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [61]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent mechanistic studies, primarily conducted in rodents, have identified a number of sites of direct action putatively mediating the effects of GLP-1-based AOMs on eating and body weight, including the area postrema and nucleus tractus solitarius (47‐49), locus coeruleus (50), hypothalamic arcuate (51, 52) and dorsomedial nuclei (53), and the lateral septal nucleus (54).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central nervous system control of food intake
Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451 · cited 9×
“In 7 of 7 cells (from 5 mice), GLP-1(7-36)amide failed to change the current in the presence of bicuculline (Figure 2, D and F), demonstrating that GABA-A receptor activation was likely responsible for the inhibitory effects of GLP-1(7-36)amide on NPY neurons.”
InfluentialDrucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 2×
“Physiologically, GLP-1 released from endocrine cells lining the gut acts peripherally (13, 42).”
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 4×
“Given the well-known role of NTS-produced GLP-1 in appetite regulation, it is tempting to speculate that peripheral administration of GLP-1 or analogs activates NTS GLP-1–positive neurons that in turn reduce appetite (22, 23).”
InfluentialObesity is associated with hypothalamic injury in rodents and humans.
Thaler, J. P., Yi, C.-X., Schur, E. A., Guyenet, S. J., Hwang, B. H., Dietrich, M. O., Zhao, X., Sarruf, D. A., Izgur, V., Maravilla, K. R., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59660 · Cited by 1,857
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“…analogs, like exenatide and lixisenatide, display a marked reduction of GE, which may contribute to short-term effects on food intake, while liraglutide and exenatide, formulated for slow release, have only a minor effect on GE, which then cannot be the mediator of the body weight effects (16, 17).”
Hypothalamic CART is a new anorectic peptide regulated by leptin
Kristensen, P., Judge, M. E., Thim, L., Ribel, U., Christjansen, K. N., Wulff, B. S., Clausen, J. T., Jensen, P. B., Madsen, O. D., Vrang, N., et al. (1998) · Nature · doi:10.1038/29993 · Cited by 1,282 · cited 1×
“…access to the brain and how they may affect the key neuronal pathways that regulate energy balance, such as the neuropeptide Y/agouti-related peptide (NPY/ AgRP) and proopiomelanocortin/cocaine-and amphetamine-regulated transcript (POMC/CART) neurons located in the arcuate nucleus (ARC) (7–11).”
Self-citationAstrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · cited 1×
“Liraglutide dose dependently lowers body weight by reducing energy intake via an overall appetite reduction (31, 32).”
NPY/AgRP Neurons Are Essential for Feeding in Adult Mice but Can Be Ablated in Neonates
Luquet, S., Perez, F. A., Hnasko, T. S., & Palmiter, R. D. (2005) · Science · doi:10.1126/science.1115524 · Cited by 1,125
Research works printed but not linked: 1
- Astrup A, Rossner S, Van Gaal L. Effects of lirag- lutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606-1616. · DOI · Paper page
Cited by
Items 901–958 of 958
Targeting Multiple Gut‐Brain Pathways in Obesity: Rationale for Combination Pharmacotherapy
Miras, A. D., & Hussain, M. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70141 · Cited by 1
Jiang, Y., Han, G., Zhang, Z., Hu, S., & Mu, M. (2026) · Comprehensive physiology · doi:10.1002/cph4.70144 · Cited by 1
“This observation highlights a general principle for incretin-based therapeutics: central effects may arise not from widespread BBB penetration, but from selective access to specialized brain regions that communicate with broader neural networks (Secher et al. 2014).”
Mechanism of GLP-1 Receptor Agonists in Weight Loss through Appetite Suppression
姚, 张. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1641386
The central amygdala integrates exogenous glucagon-like peptide 1 signalsPreprint
Duran, M., Zeng, N., Cutts, E. J., Habegger, K. M., & Hardaway, J. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.06.716705
Machaba, K. E., & Chuturgoon, A. A. (2026) · Scientific African · doi:10.1016/j.sciaf.2026.e03361
The Hungry Mind: Exploring Hypothalamic Dysfunction in Prader-Willi Syndrome
Berg, R., & Zaim, N. (2026) · Springer eBooks · doi:10.1007/978-3-032-10099-3_32
Tudosie, A. C., Marin, L.-M., Popa, S. G., & Golli, A. L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083628 · Cited by 2
Genetic variability in the leptin-melanocortin pathway and its role in weight loss
Monteiro, M. P., Guimarães, M., Monteiro, M. P., Pereira, S. S., & Azevedo, L. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102377
“GLP-1R is likely involved in the activation of POMC-expressing neurons and inhibition of AgRP/ NPY-expressing neurons, the pathway through which the pharmacological use of GLP-1RA induces body weight reduction for obesity treatment [92].”
Peng, T., Liang, W., Wei, J., Ding, N., Tang, X., & Zhang, Z. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s590529
“25 Their combination may lead to complex interactions, such as pathway cross-talk, signal amplification, or compensatory effects.”
Transient Hyperprolactinemia Associated With Semaglutide in a Patient With Hashimoto’s Thyroiditis
Guimarães, G. N. F. (2026) · Case Reports in Medicine · doi:10.1155/carm/3016596
Palladino, G., Patarra, R., Li, Z., Rossner, M. J., & Wehr, M. C. (2026) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2026.1789400
“The main function of this class is to link metabolic and hormonal signaling to brain activity, also playing roles in neuroendocrine regulation and stress response (Reul and Holsboer, 2002; Secher et al., 2014).”
Navigating gut-liver metabolic homeostasis: the role of the autonomic nervous system
Sun, R., He, J.-L., Cheng, Y., Yu, S.-R., Zhang, M.-N., Yang, M., Chen, K., Wu, M.-Y., & Chai, J. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.37 · Cited by 1
Clinical and economic aspects of semaglutide use in the treatment of obesity
Tibilova, A. L., Kozaeva, D. D., Aslakhanova, R. R., Tedety, V. Z., Tazurkaeva, M. Z., Gurtsieva, D. E., Kanteeva, E. E., Gabueva, M. S., Guatsaeva, V. I., Dzhigkaeva, A. M., et al. (2026) · FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology · doi:10.17749/2070-4909/farmakoekonomika.2026.369
Regulators of appetite in mammals—old and new players
Fernandes, J. H., Silva, J. D., Costa, M. D., & Maciel, P. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag020 · Cited by 1
Jovanovic, V. M., Narisu, N., Bonnycastle, L. L., Castellano, D., Ryu, S., Tharakan, R., Mesch, K. T., Chen, Q., Erol, F. M. B., Glover, H. J., et al. (2026) · Stem Cell Reports · doi:10.1016/j.stemcr.2026.102958 · Cited by 1
Han, S., Shin, J., Kim, J. C., & Na, D. H. (2026) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-026-00815-4
“Activation of hypothalamic GLP-1 receptors increases the secretion of anorexigenic peptides while decreasing the secretion of orexigenic peptides (Secher et al. 2014; Geloneze et al. 2017).”
Effect of emerging antiobesity and antidiabetic drugs on atherosclerosis
Armentaro, G., Severini, G., Pastura, C. A., Scarcelli, M. R., Cassano, V., & Sciacqua, A. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04438-3
“Thanks to its central hypothalamic inhibitory effects on appetite [32], GLP-1 stimulates both the feeling of fullness and satiety, acting directly on proopiomelano-cortin (POMC)-secreting neurons in the arcuate nucleus, increasing melanocortin (MSH) secretion and the expression of its MC4R receptor…”
Rationale of renewed efforts in developing MC4R modulators to treat metabolic disorders
Feng, W., Zhou, Q., & Wang, M. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.06.035
“GLP-1R is expressed in arcuate POMC neurons, where GLP-1 or exendin-4 directly depolarizes these neurons and increases firing rate ― an effect blocked by GLP-1R antagonism 169 .”
Vignera, S. L., Fioriglio, C., & Condorelli, R. A. (2026) · Diagnostics · doi:10.3390/diagnostics16131979
“GLP-1 potently suppresses appetite through central nervous system pathways involving the hypothalamus and brainstem, delays gastric emptying, inhibits glucagon secretion, and promotes satiety [21,22].”
Saponaro, C., Imbernón, M., Louvet, I., Deligia, E., Chen, S., Davies, I., Acosta-Montalvo, A., Moreno-Lopez, M., Wemelle, E., Kothegala, L., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06779-2
“Within this context, liraglutide particularly affects pro-opiomelanocortin (POMC) neurons [14–16], which interact with tanycytes to integrate circulating glucose signals [17] and regulate insulin release via parasympathetic nerve modulation [18].”
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
Transient Effects of Exenatide on Intraocular Pressure in a Rat Bone Defect Model
Özcan, C., Dellalbaşı, A. B., Doğan, E., Uğur, F., & Taşkın, R. (2026) · Dicle Üniversitesi Veteriner Fakültesi Dergisi · doi:10.47027/duvetfd.1858619
Dąbek, K., Czyżak, K., Marzec, U., Cyrkler, A., Cieślak, N., Chodkowska, A., Rajca, E., Giza, A., Paulina, G. I. Z. A., & Wymoczył, K. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5113
Chen, J., Liu, K.-W., Huang, Y., Meyerowitz‐Katz, G., Tsai, T., & Su, P. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261460592 · Cited by 1
“35 GLP-1 receptor activation couples central appetite regulation with improved hepatic lipid handling and anti-inflammatory signaling, 36,37 whereas SGLT2 inhibition drives natriuresis, hemodynamic reprogramming, and uric acid lowering.”
Turner, M., Singh, M. D., & Evans, I. D. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01892-y
“…elenolic acid simultaneously induces secretion of glucagon-like peptide -1 called liraglutide in the arcuate nucleus of hypothalamus, effecting upregulations in signalling of the anorexi - genic POMC and CART peptides, mediating weight loss processes (Jelsing et al. 2012; Secher et al. 2014).”
The application of GLP-1 receptor agonists in obesity due to MC4R deficiency
Ding, M., Luo, Y., & Ji, L. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.58
Lipid sensing and brain hormone receptors in food intake and glucose regulation
Garrido, A. N., Lyons, S. A., MOSLEMIAN, D., Beaudry, J. L., & Lam, T. K. T. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01278-1
Kim, T., Seo, J., Kang, S., Kim, H. K., Lee, B., Lee, J., & Go, G. (2026) · Food Science and Biotechnology · doi:10.1007/s10068-026-02259-w
Brain-Wide Connectivity of GLP1R Neurons in the Thalamic Reticular Nucleus
Zhang, X., Zhu, S., Lan, J., Duan, S., Han, Y., & Shi, P. (2026) · Journal of Integrative Neuroscience · doi:10.31083/jin52117
Zhang, S., Liu, S., Zhou, M., Wang, J., Zhang, Y., Zhong, H., & Ning, G. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06090-6
“…as well as central mechanisms in which GLP-1RAs act on hypothalamic neurons to inhibit the neuropeptide Y (NPY)/agouti-related protein (AgRP) pathway and enhance the pro-opiomelanocortin (POMC)/cocaine-and amphet-amine-regulated transcript (CART) pathway, ultimately suppressing appetite [99, 100 ].”
Kurowski, M., Rekiel, K., Marcinkowska, A., Ratajczyk, O., Urbanowicz, P., Iwankiewicz, S., Grzelczak, W., & mierczak, Z. K. (2026) · Medical Journal of Cell Biology · doi:10.2478/acb-2026-0005
Wang, R., Liu, Q., Lu, C., Chen, K., Liu, S., Guo, L., Guo, Z., Liu, Y., & Zhang, Y. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119206
Gómez-Maldonado, I., Rodríguez-Arana, A., Tamayo-Pinzón, A., Albornoz-Suárez, J. E., Lopez-Franco, M. J., Mejia-Manrique, J. A., Forero-Caycedo, J. J., Rojas-Rodríguez, L. C., Buitrago-Ricaurte, N., Gaviria-Carrillo, M., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167108
“Furthermore, Secher et al. investigated the long-term effects of liraglutide on the expression of key appetite-regulating genes within the arcuate nucleus (ARC) [130].”
Le, T. T. V., Gao, T., Cheng, X., Le, Q. M., Li, M., Wei, X., Li, M., Yao, L., Sun, M., He, M., et al. (2026) · Comprehensive physiology · doi:10.1002/cph4.70241
Dedanishvili, N. S., Pyurveev, S. S., Brus, T. V., & Vasiliev, A. G. (2026) · Бюллетень Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук · doi:10.29413/abs.2026-11.3.20
Balbotkina, E. V., Goncharov, M. A., Belyakov, G. V., Шкода, А. О., & Кутина, А. В. (2026) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1134/s002209302604006x
“…we recorded a significant decrease in water intake (2.5-fold) and food intake (2.1–2.7-fold over two days), which is well known for GLP-1 agonists and is explained by their central action through receptors in the area postrema and hypothalamus, suppressing appetite and thirst [25–27].”
InfluentialMartínez‐Corral, I., Monaco, N., Brierley, D. I., & Imbernón, M. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70636 · Cited by 1
Xie, Y., Zhang, X., & Chen, B. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1913929
Liu, Q., Chen, L., Zhang, M., Wang, Z., Wang, X., Dong, Y., Wang, K., Jiang, C., & Yin, Y. (2026) · NeuroMolecular Medicine · doi:10.1007/s12017-026-08945-6
Hammad, M. A. M., Perelmuter, S., Furlan, V. A., Nakamura, H., Rubin, R. S., & Yih, J. (2026) · Research Square · doi:10.21203/rs.3.rs-10580243/v1
Schifano, F., Luca, M. A. D., Bonaccorso, S., Arillotta, D., Floresta, G., Martinotti, G., Papanti, G. D., Corkery, J., Chiappini, S., & Guirguis, A. (2026) · Current Psychiatry Reports · doi:10.1007/s11920-026-01709-w · Cited by 1
“Although GLP-1 RAs were not developed as centrally acting drugs, their documented [ 74 ] penetration of a range of brain regions and engagement of neural circuits regulating appetite and reward raise important questions regarding broader psychopharmacological effects.”
Liu, C., Sun, C., Kan, C., Sun, X., & Zhu, L. (2026) · Reviews in the Neurosciences · doi:10.1515/revneuro-2026-0110
“In the brain, GLP-1 receptor (GLP-1R) signaling regulates feeding, reward, glucose homeostasis, and neuroplasticity, with hypothalamic GLP-1R pathways contributing importantly to the anorectic and weight-reducing e ff ects of GLP-1R agonists (Secher et al. 2014).”
Kalafati, I. P., Krongauz, D. L., Bosco, A., Noto, A., Piras, C., Kafyra, M., Dessì, A., Mauri, M., Atzori, L., Weinberger, A., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70220
Microbiota-Gut-Brain Axis Mechanisms in Cognitive Impairment Associated with Central Obesity
Huang, T., Hao, Z., Shen, J., Lai, T., Wu, Y., Zhu, X., Wu, H., & Bao, C. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00755-y
“These limitations make it difficult to determine whether VAT is an upstream contributor, a marker of metabolic dysfunction, or a parallel correlate of brain aging.”
Goñi, J. A., Sánchez‐Barba, M., López, G. P., Megías, S. M., & Albarrán, O. G. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.09.005
Jo, D., Song, D. J., Jeong, S. W., & Song, J. (2026) · Current Molecular Pharmacology · doi:10.1016/j.cmp.2026.09.011
Paraventricular Hypothalamic GLP-1R Neurons Mediate Propofol-Induced Suppression of Food Intake
Liang, J., Yin, M., Yang, S., Zhang, L., & Han, Y. (2026) · Journal of Integrative Neuroscience · doi:10.31083/jin52398
Skowron, W., Skowron, M., Łapot, M., Hober, K., Krupnik, D., Bzdak, W., Szwemińska, P., Górak, J., & Neumann, W. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6241
“Experimental studies have demonstrated that GLP-1 receptor activation stimulates anorexigenic pathways while suppressing orexigenic neuronal activity (Secher et al., 2014).”
Klusek, K., Batory, M., Jakubowski, J., Kraska, K., Krasucka, N., Zynkowska, A., Skrzyniarz, A. M., Kiełbus, M., Oziębło, J., & Kijowska, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6114
Lele, F., Yuying, G., Liu, J., Shuwen, H., & Jing, Z. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1923456
“GLP-1 also participates in gut–brain regulation of appetite and energy balance through peripheral and central GLP-1 receptor signaling (Gribble and Reimann, 2016; Secher et al., 2014; Hölscher, 2010).”
Maiolino, G., Martínez‐García, M. Á., Gozal, D., Lombardi, C., Fioretto, P., Vettor, R., Busetto, L., & Pengo, M. F. (2026) · Obesity Reviews · doi:10.1111/obr.70238
Findeis, J., Koschker, A., & Winterholler, M. (2026) · Epilepsia · doi:10.1002/epi.70527
Hoffmann, K., Pucek, W. F., Skrzypek, W., Kierzkowski, F., Ratajczak, P., Maggio, V., Rizzo, M., El-Tanani, M., Rabbani, S. A., Bhongade, B. A., et al. (2026) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2026.17560
Lakshmi, S. M., Singh, V., Vanangamudi, M., Taj, T., Shahin, H., Nath, R., Dutta, G., Avvari, S. K., Sridhar, S. B., Panigrahy, U. P., et al. (2026) · European Journal of Neuroscience · doi:10.1111/ejn.70718
Cassano, D., Fernández, G., Cornejo, M. P., Sheybani-Deloui, S., Aguggia, J. P., Cantel, S., Fehrentz, J., Habib, A. M., Rolland, L., Ravier, M. A., et al. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124754
BindingDB Entry 50022117: Binding sites and design strategies for small molecule GLP-1R agonists.
BindingDB (2025) · UC San Diego · doi:10.7270/q2474gk6
Metadata
- Authors
- Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., Schäffer, L., Tang-Christensen, M., Verma, S., Witgen, B. M., Vrang, N., & Bjerre Knudsen, L.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Gubra (Denmark) (DK)
- Oregon National Primate Research Center (US)
- Oregon Health & Science University (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2014-09-09
- Volume
- 124
- Issue
- 10
- Pages
- 4473-4488
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4215190
- OpenAlex
- W2014156217
- Cited by
- 961
- References
- 95
- Citations by year
- 2026: 100 · 2025: 126 · 2024: 123 · 2023: 85 · 2022: 77 · 2021: 93 · 2020: 56 · 2019: 63 · 2018: 62 · 2017: 65 · 2016: 52 · 2015: 53 · 2014: 5
- FWCI
- 28.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- liraglutide, GLP-1 receptor, arcuate nucleus, weight loss, hypothalamus, proopiomelanocortin neurons, neuropeptide Y, agouti-related protein, GABAergic inhibition, circumventricular organs, GLP-1 analogues, appetite regulation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Cocaine- and Amphetamine-Regulated Transcript Protein, Animals, Arcuate Nucleus of Hypothalamus, Body Weight, Disease Models, Animal, Electrophysiology, Hypothalamus, Male, Mice, Transgenic, Nerve Tissue Proteins, Neurons, Paraventricular Hypothalamic Nucleus, Pro-Opiomelanocortin, Vagus Nerve, Weight Loss, Rats, Sprague-Dawley, Receptors, Glucagon, Mice, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.